NEW YORK (GenomeWeb News) – CyVek today said that it has raised $5.5 million in a Series D financing round.

The funding will go toward building an infrastructure to commercialize the company's multiplex immunoassay technology called CyPlex, which uses a microfluidic cartridge for analyzing multiple biomarkers from small amounts of biological samples. CyPlex will be used initially for life sciences, drug discovery, and clinical research applications, the Wallingford, Conn.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.